Drugs / CoV2 preS dTM
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04537208 | Sep 2020 → Nov 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05405283 | Jun → Jul 2022 | — | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoV2 preS dTM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05405283 ↗ |
| Modality | Vaccine | “CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system” PMID 33887209 ↗ Apr 2021 |